Department Of Internal Medicine 5
201. Heart failure with preserved ejection fraction in cancer patients and survivors. A scientific statement of the Heart Failure Association of the ESC and the ESC Council of Cardio-Oncology
202. The right heart in patients with cancer. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology
203. Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021
204. Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021
205. Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021
206. Sputum culture reversion in longer treatments with bedaquiline, delamanid, and repurposed drugs for drug-resistant tuberculosis
207. Anemia prevalence in women of reproductive age in low- and middle-income countries between 2000 and 2018
208. Anemia prevalence in women of reproductive age in low- and middle-income countries between 2000 and 2018
209. Anemia prevalence in women of reproductive age in low- and middle-income countries between 2000 and 2018
210. Anemia prevalence in women of reproductive age in low- and middle-income countries between 2000 and 2018
211. Anemia prevalence in women of reproductive age in low- and middle-income countries between 2000 and 2018
212. Anemia prevalence in women of reproductive age in low- and middle-income countries between 2000 and 2018
213. Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019 A Systematic Analysis for the Global Burden of Disease Study 2019
214. Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019 A Systematic Analysis for the Global Burden of Disease Study 2019
215. Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019 A Systematic Analysis for the Global Burden of Disease Study 2019
216. Analysis of Retracted Publications on Artificial Intelligence: Trends, Ethical Concerns, and Scientific Integrity
217. Association of four genetic variants with colorectal cancer in kazakhstan population
218. Recent therapeutic advances in gynecologic oncology: evolving roles of immunotherapy, antibody–drug conjugates, and clinical trial innovations
219. Immunogenic Properties and Safety of a Quadrivalent Inactivated Subunit Adjuvanted Influenza Vaccine in Adults Aged 18 to 85 Years at the End of the COVID-19 Pandemic in the 2022–2023 Season
220. Calcified pancreatoduodenal artery aneurysm with filiform celiac stenosis: Follow up for ~6 years (70 months) with no intervention
221. Retraction Note: The relationship of double-stranded DNA breaks in blood lymphocytes and obesity without carbohydrate metabolism disorder (Molecular and Cellular Biochemistry, (2022), 477, 9, (2249-2255), 10.1007/s11010-022-04440-1)
222. The relationship of double-stranded DNA breaks in blood lymphocytes and obesity without carbohydrate metabolism disorder
223. The Influence of Vitamin D on Pregnancy and Outcomes: Current Knowledge and Future Perspectives
224. Organ transplantation in Central Asia countries: A review and challenges in the development of organ donation
225. Global, regional, and national age-sex-specific burden of diarrhoeal diseases, their risk factors, and aetiologies, 1990–2021, for 204 countries and territories: a systematic analysis for the Global Burden of Disease Study 2021
226. Global, regional, and national age-sex-specific burden of diarrhoeal diseases, their risk factors, and aetiologies, 1990–2021, for 204 countries and territories: a systematic analysis for the Global Burden of Disease Study 2021
227. Inositols in the ovaries: activities and potential therapeutic applications
228. Association of plasminogen activator inhibitor-1 and cardiovascular events development in patients with prediabetes
229. A global action agenda for turning the tide on fatty liver disease
230. A global action agenda for turning the tide on fatty liver disease
231. A global action agenda for turning the tide on fatty liver disease
232. A global action agenda for turning the tide on fatty liver disease
233. A global action agenda for turning the tide on fatty liver disease
234. A global action agenda for turning the tide on fatty liver disease
235. Advancing the global public health agenda for NAFLD: a consensus statement
236. Advancing the global public health agenda for NAFLD: a consensus statement
237. Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021
238. Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021
239. Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021
240. Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021
241. Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021
242. Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021
243. Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021
244. Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021
245. Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021
246. Global, regional and national burden of dietary iron deficiency from 1990 to 2021: a Global Burden of Disease study
247. Global, regional and national burden of dietary iron deficiency from 1990 to 2021: a Global Burden of Disease study
248. Global, regional and national burden of dietary iron deficiency from 1990 to 2021: a Global Burden of Disease study
249. Global, regional and national burden of dietary iron deficiency from 1990 to 2021: a Global Burden of Disease study
250. Global, regional and national burden of dietary iron deficiency from 1990 to 2021: a Global Burden of Disease study
1 3 4 5 6 7 10